Comparison of an 18F labeled deravative of vasoactive intestinal peptide and 2-deoxy-2-[18F)fluoro-D-glucose in nude mice bearing breast cancer xenografts

Molecular Imaging and Biology

Volumn 4, Issue 5, 2002, Pages 369-379

  Jagoda, Elaine M ^a   Aloj, Luigi ^c   Seidel, Jurgen ^a   Lang, Lixin ^a   Moody, Terry W ^b   Green, Shielah ^a   Caraco, Corradina ^d   Daube Witherspoon, Margaret ^e   Green, Michael V ^a   Eckelman, Willian C ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Centro per la Medicina Nucleare   (Italy)

^d Ist di Med Sperimentale e Biotech   (Italy)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

18F dVIP and FDG in tumor mice; 3H deoxyglucose; Biodistribution studies; Breast carcinoma; FDG; PET imaging of xenograft tumors; PET radiopharmaceuticals; Receptors; T 47D and MDA MB231 human breast carcinomas in nude mice; Tumor mouse models of human breast cancer; Vosoactive intestinal peptide (VIP)

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE F 18; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CONCENTRATION (PARAMETERS); CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; GAMMA RADIATION; IMAGE ANALYSIS; IN VIVO STUDY; KIDNEY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION MEASUREMENT; TUMOR XENOGRAFT;

ANIMALIA; MUS MUSCULUS;

EID: 0036764754     PISSN: 15361632     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1536-1632(02)00019-7     Document Type: Article

References (50)

1. 18F]-FDG in oncology: a clinical update. Nucl. Med. Biol. 23: 717-736; 1996.
2. 18F] fluorodeoxyglucose and positron emission tomography. Neurology. 32: 1323-1329; 1982.
3. Larson, S.M.; Weiden, P.L.; Grunbaum, Z.; et al. Positron imaging feasibility studies. II: Characteristics of 2- deoxyglucose uptake in rodent and canine neoplasms: concise communication. J. Nucl. Med. 22: 875-879; 1981.
4. Som, P.; Atkins, H.L.; Bandoypadhyay, D.; et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J. Nucl. Med. 21: 670-675; 1980.
5. Kubota, R.; Kubota, K.; Yamada, S.; et al. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J. Nucl. Med. 35: 104-112; 1994.
6. McKeehan, W.L. Glycolysis, glutaminolysis and cell proliferation. Cell Biol. Int. Rep. 6: 635-650; 1982.
7. Paul, R.; Johansson, R.; Kellokumpu-Lehtinen, P.L.; et al. Tumor localization with 18F-2-fluoro-2-deoxy-D-glucose: comparative autoradiography, glucose 6-phosphatase histochemistry, and histology of renally implanted sarcoma of the rat. Res. Exp. Med. 185: 87-94; 1985.
8. Weber, G. Enzymology of cancer cells (second of two parts). N. Engl. J. Med. 296: 541-551; 1977.
9. 18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest. Radiol. 22: 360-371; 1987.
10. Kubota, K.; Matsuzawa, T.; Fujiwara, T.; et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J. Nucl. Med. 31: 1927-1932; 1990.
11. Minn, H.; Joensuu, H.; Ahonen, A.; et al. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer. 61: 1776-1781; 1988.
12. Brown, R.S.; Wahl, R.L. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 72: 2979-2985; 1993.
13. Yamamoto, T.; Seino, Y.; Fukumoto, H.; et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem. Biophys. Res. Commun. 170: 223-230; 1990.
14. Brown, R.S.; Fisher, S.J.; Wahl R.L. Autoradiographic evaluation of the intra-tumoral distribution of 2- deoxy-D-glucose and monoclonal antibodies in xenografts of human ovarian adenocarcinoma. J. Nucl. Med. 34: 75-82; 1993.
15. Torizuka, T.; Tamaki, N.; Inokuma, T.; et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J. Nucl. Med. 36: 1811-1817; 1995.
16. Aloj, L.; Caraco, C.; Jagoda, E.; et al. Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-Dglucose uptake in A431 and T47D cells in culture. Cancer Res. 59: 47090-4714; 1999.
17. Waschek, J.A. Vasoactive intestinal peptide: an important trophic factor and developmental regulator? Dev. Neurosci. 17: 1-7; 1995.
18. el Battari, A.; Martin, J.M.; Luis, J.; et al. Solubilization of the active vasoactive intestinal peptide receptor from human colonic adenocarcinoma cells. J. Biol. Chem. 263: 17685-17689; 1988.
19. Svoboda, M.; De Neef, P.; Tastenoy, M.; et al. Molecular characteristics and evidence for internalization of vasoactive-intestinal-peptide (VIP) receptors in the tumoral rat-pancreatic acinar cell line AR 4-2 J. Eur. J. Biochem. 176: 707-713; 1988.
20. Virgolini, I.; Yang, Q.; Li, S.; et al. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Cancer Res. 54: 690-700; 1994.
21. Moody, T.W.; Cuttitta, F. Growth factor and peptide receptors in small cell lung cancer. Life Sci. 52: 1161-1173; 1993.
22. Zia, H.; Hida, T.; Jakowlew, S.; et al. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. Cancer Res. 56: 3486-3489; 1996.
23. Gespach, C.; Bawab, W.; de Cremoux, P.; et al. Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells. Cancer Res. 48: 5079-5083; 1988.
24. Moody, T.W.; Leyton, J.; Gozes, I.; et al. VIP and breast cancer. Ann. N.Y. Acad. Sci. 865: 290-296; 1998.
25. Moody, T.W.; Leyton, J.; Chan, D.; et al. VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells. Breast Cancer Research Treat. 68: 55-64; 2001.
26. Moody, T.W. Peptides and growth factors in non-small cell lung cancer. Peptides. 17: 545-555; 1996.
27. Wulff, B.; Moller Knudsen, S.; Adelhorst, K.; et al. The C-terminal part of VIP is important for receptor binding and activation, as evidenced by chimeric constructs of VIP/secretin. FEBS. Lett. 413: 405-408; 1997.
28. Virgolini, I.; Kurtaran, A.; Raderer, M.; et al. Vasoactive intestinal peptide receptor scintigraphy. J. Nucl. Med. 36: 1732-1739; 1995.
29. Lang, L.; Eckelman, W.C. One step synthesis of F-18 labeled [F-18]-N-succinimidyl 4-(fluoromethyl)benzoate for protein labeling. Appl. Radiat. Isot. 45: 1155-1163; 1994.
30. Lang, L.; Eckelman, W.C. Labeling proteins at high specific activity using N-succinimidyl 4-[F-18] fluoromethyl benzoate. Appl. Radiat. Isot. 48: 169-173; 1997.
31. Moody, T.W.; Leyton, J.; Unsworth, E.; et al. (Arg15, Arg21) VIP: evaluation of biological activity and localization to breast cancer tumors. Peptides. 19: 585-592; 1998.
32. Adams, H.R.; Channing, M.A.; Divel, J.E.; et al. Trend analysis of quality control data. In: Emran, A., ed. Chemists' views of imaging centers. New York: Plenum Press; 1995: 175-188.
33. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J. Nucl. Med. 27: 235-238; 1986.
34. 125I-labeled anti-Tac disulfide-stabilized Fv fragments in nude mice with interleukin 2 alpha receptor-positive tumor xenografts. Cancer Res. 55: 5323-5329; 1995.
35. Seidel, J.; Gandler, W.R.; Weinberger, I.N.; et al. Collimatorless projection imaging of positron emitters with an opposed pair of BGO scintillation cameras. J. Nucl. Med. 36: 177P; 1995.
36. Munson, P.J.; Rodbard, D. Ligand: a versatile computerized approach for characterization of ligand binding systems. Anal. Biochem. 107: 220-239; 1980.
37. Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254; 1976.
38. Sambrook, J.; Fritsch, E.F.; Maniatis, T. Molecular cloning: a laboratory manual. 2nd edition. Cold Spring Harbor, NY: Cold Spring Laboratory; 1989.
39. Aloj, L.; Caraco, C.; Jagoda, E.; et al. Facilitative and sodium dependent glucose transporter mRNA expression in nude mice tumor xenografts: correlation with deoxyglucose uptake. J. Nucl. Med. 37: 254P-255P; 1996.
40. 18F]FDG and a dedicated animal scanner. Life Sciences. 71:1293-1301; 2002.
41. Brown, R.S.; Leung, J.Y.; Fisher, S.J.; et al. Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? J. Nucl. Med. 36: 1854-1861; 1995.
42. Kubota, R.; Yamada, S.; Kubota, K.; et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J. Nucl. Med. 33: 1972-1980; 1992.
43. Kubota, R.; Kubota, K.; Yamada, S.; et al. Active and passive mechanisms of [fluorine-18] fluorodeoxyglucose uptake by proliferating and prenecrotic cancer cells in vivo: a microautoradiographic study. J. Nucl. Med. 35: 1067-1075; 1994.
44. Waschek, J.A.; Richards, M.L.; Bravo, D.T. Differential expression of VIP/PACAP receptor genes in breast, intestinal, and pancreatic cell lines. Cancer Lett. 92: 143-149; 1995.
45. Luis, J.; Martin, J.M.; el Battari, A.; et al. The vasoactive intestinal peptide (VIP) receptor: recent data and hypothesis. Biochimie. 70: 1311-1322; 1988.
46. Virgolini, I.; Raderer, M.; Kurtaran, A.; et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N. Engl. J. Med. 331: 1116-1121; 1994.
47. Raderer, M.; Becherer, A.; Kurtaran, A.; et al. Comparison of iodine-123-vasoactive intestinal peptide receptor scintigraphy and indium-111-CYT-103 immunoscintigraphy. J. Nucl. Med. 37: 1480-1487; 1996.
48. Virgolini, I. Mack Forster award lecture. Receptor nuclear medicine: vasointestinal peptide and somatostatin receptor scintigraphy for diagnosis and treatment of tumour patients. Eur. J. Clin. Invest. 27: 793-800; 1997.
49. Chatziioannou, A.F.; Cherry, S.R.; Shao, Y.; et al. Performance evaluation of microPET: a high-resolution lutetium oxyorthosilicate PET scanner for animal imaging [see comments]. J. Nucl. Med. 40: 1164-1175; 1999.
50. Siegel, S.; Vaquero, J.J.; Aloj, L.; et al. Initial results from a PET/Planar small animal imaging system. IEEE Trans. Nucl. Sci. 46: 571-575; 1999.